Business Wire22d
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...
Business Wire1mon
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine ... commonly administered to dogs as part of combination distemper/kennel cough vaccines for decades.
Yahoo Finance25d
First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal COVID-19 Vaccine Candidate
December 09, 2024--(BUSINESS WIRE)--CyanVac LLC, a clinical-stage biotechnology company developing intranasal ... administered to dogs as part of combination distemper/kennel cough vaccines ...